Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-14 4:38 pm Sale |
2021-12-31 | 13G | AnaptysBio, Inc. ANAB |
Point72 Asset Management, L.P. | 271,229 1.000% |
-1,106,713 (-80.32%) |
Filing History |
| 2022-02-14 4:37 pm Purchase |
2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
Point72 Asset Management, L.P. | 3,007,138 5.800% |
365,885 (+13.85%) |
Filing History |
| 2022-02-14 4:36 pm Sale |
2021-12-31 | 13G | Praxis Precision Medicines, Inc. PRAX |
Point72 Asset Management, L.P. | 163,103 5.500% |
-5,608 (-3.32%) |
Filing History |
| 2022-02-14 4:35 pm Unchanged |
2021-12-31 | 13G | Blue Owl Capital Inc. OWL |
Point72 Asset Management, L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2022-02-14 4:35 pm Sale |
2021-12-31 | 13G | Prometheus Biosciences, Inc. RXDX |
Point72 Asset Management, L.P. | 1,982,561 5.100% |
-665,463 (-25.13%) |
Filing History |
| 2022-02-14 4:34 pm Sale |
2021-12-31 | 13G | Allena Pharmaceuticals, Inc. ALNAQ |
Point72 Asset Management, L.P. | 0 0.000% |
-4,000,000 (Position Closed) |
Filing History |
| 2022-02-14 4:34 pm Sale |
2021-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
Point72 Asset Management, L.P. | 2,420,309 5.100% |
-1,908,721 (-44.09%) |
Filing History |
| 2022-02-14 4:34 pm Purchase |
2021-12-31 | 13G | Affimed N.V. AFMD |
Point72 Asset Management, L.P. | 1,185,559 9.900% |
604,098 (+103.89%) |
Filing History |
| 2022-02-14 4:33 pm Sale |
2021-12-31 | 13G | Regulus Therapeutics Inc. RGLS |
Point72 Asset Management, L.P. | 241,158 1.600% |
-321,544 (-57.14%) |
Filing History |
| 2022-02-14 4:33 pm Purchase |
2021-12-31 | 13G | Acorda Therapeutics, Inc. ACOR |
Point72 Asset Management, L.P. | 23,214 4.100% |
23,214 (New Position) |
Filing History |
| 2022-02-14 4:32 pm Purchase |
2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
Point72 Asset Management, L.P. | 472,864 2.200% |
46,702 (+10.96%) |
Filing History |
| 2022-02-14 4:32 pm Sale |
2021-12-31 | 13G | Golar LNG Limited GLNG |
Point72 Asset Management, L.P. | 4,406,367 4.100% |
-1,174,969 (-21.05%) |
Filing History |
| 2022-02-14 4:31 pm Unchanged |
2021-12-31 | 13G | Bakkt Holdings, Inc. BKKT |
Point72 Asset Management, L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2022-02-14 4:31 pm Sale |
2021-12-31 | 13G | Forte Biosciences, Inc. FBRX |
Point72 Asset Management, L.P. | 44 0.100% |
-27,798 (-99.84%) |
Filing History |
| 2022-02-14 4:29 pm Purchase |
2021-12-31 | 13G | Avalo Therapeutics, Inc. AVTX |
Point72 Asset Management, L.P. | 2,088 5.400% |
1 (+0.05%) |
Filing History |
| 2022-02-14 4:28 pm Purchase |
2021-12-31 | 13G | Atara Biotherapeutics, Inc. ATRA |
Point72 Asset Management, L.P. | 185,366 5.200% |
2,645 (+1.45%) |
Filing History |
| 2022-02-14 4:27 pm Purchase |
2021-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
Point72 Asset Management, L.P. | 2,657,962 5.300% |
107,226 (+4.20%) |
Filing History |
| 2022-02-14 4:26 pm Purchase |
2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Point72 Asset Management, L.P. | 1,760,248 5.000% |
8,685 (+0.50%) |
Filing History |
| 2022-02-14 4:25 pm Sale |
2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Point72 Asset Management, L.P. | 2,244 0.100% |
-114,948 (-98.09%) |
Filing History |
| 2022-02-11 5:05 pm Purchase |
2022-02-01 | 13G | uniQure N.V. QURE |
Point72 Asset Management, L.P. | 3,611,691 7.800% |
3,143,854 (+672.00%) |
Filing History |